Vitiligo Pipeline Analysis Demonstrates Novel 22+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

DelveInsight's, "Vitiligo Pipeline Insight, 2023," report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the Vitiligo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Vitiligo Emerging Drugs, the Vitiligo pipeline analysis report provides a 360° view of the Vitiligo pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Vitiligo pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the Vitiligo Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Vitiligo clinical trials studies, Vitiligo NDA approvals (if any), and product development activities comprising the technology, Vitiligo collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from the Vitiligo Pipeline Report

• Over 22+ Vitiligo companies are evaluating 22+ Vitiligo pipeline therapies in various stages of development, and their anticipated acceptance in the Vitiligo market would significantly increase market revenue.

• The leading Vitiligo Companies include Incyte Corporation, Amgen, Boston Pharmaceuticals, Arcutis Biotherapeutics, Pfizer, Dermavant Sciences, Clinuvel Pharmaceuticals, Celgene, TWi Biotechnology, AXIM Biotechnologies, Arrien Pharmaceuticals, and others.

• Promising Vitiligo Pipeline Therapies inclues Cerdulatinib, Ruxolitinib, AC-1101, ATI-1777, QLT-450, AMG 714, PF-06651600, ANB030, ARQ-252, BNZ-1, TT-01, and others.

• The Vitiligo companies and academics are working to assess challenges and seek opportunities that could influence Vitiligo R&D. The Vitiligo pipeline therapies under development are focused on novel approaches to treat/improve Vitiligo.

To explore more information on the latest breakthroughs in the Vitiligo treatment landscape of the report, visit here Vitiligo Pipeline Outlook @ https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Vitiligo Overview

Vitiligo is a complex pigment disorder that involves the skin, the hair, and occasionally the mucous membranes. It is a long-term condition where pale white patches develop on the skin. Vitiligo can affect any area of skin, but it commonly happens on the face, neck and hands. Vitiligo appears clinically as milk-white irregularly oval patches of skin, which are small at the beginning but enlarge gradually. The hair growing in the depigmented area is also white. Vitiligo can be triggered by stress to the melanin pigment-producing cells of the skin, the melanocytes. The triggers, which range from sunburn to mechanical trauma and chemical exposures, ultimately cause an autoimmune response that targets melanocytes, driving progressive skin depigmentation.

Recent Developmental Activities in the Vitiligo Treatment Landscape

• In March 2020, Edesa Biotech entered into a collaborative research agreement with the National Research Council (NRC) of Canada for the development of monoclonal antibody candidates for vitiligo as well as other autoimmune diseases. Under the terms of the agreement, multiple monoclonal antibodies will be produced by the National Research Council of Canada from which Edesa will identify a lead candidate to take into IND-enabling studies. The NRC will grant an exclusive worldwide license for the antibodies arising from the project to Edesa.

• In January 2020, Eli Lilly and Company announced a definitive agreement to acquire Dermira for approximately $1.1 billion, in an all-cash transaction. Dermira is a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions such as acne, atopic dermatitis, and Vitiligo.

• Arcutis Biotherapeutics in-licensed SHR0302, the active ingredient in ARQ-252, a potent and highly selective inhibitor of janus kinase type 1 (JAK1), from a Chinese company Jiangsu Hengrui Medicine Co. Many signalling molecules rely on the JAK pathway - especially JAK1 - which plays a central role in immune system function. Arcutis believes this compound has a promising treatment potential without hematopoietic adverse effects typically associated with JAK2 inhibition. Arcutis initiated a Phase 2a study in March 2021 to evaluate ARQ-252 as a potential treatment for vitiligo.

• AnaptysBio with its ANB030 (Anti-PD-1 Agonist) program is moving into a healthy volunteer Phase 1 trial, with top-line data anticipated in mid-2021. If all goes well, Phase 2 clinical trials in alopecia areata and vitiligo are scheduled for Q4 2021.

Find the information related to the Vitiligo Emerging therapies and companies, visit here Vitiligo Ongoing Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Vitiligo Pipeline Therapeutics Assessment

• Ruxolitinib: Incyte Corporation
Ruxolitinib is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The therapy is currently under Phase III clinical development for the treatment of vitiligo.

• AMG-714: Amgen
AMG-714, a fully human immunoglobulin monoclonal antibody (IgG1κ), binds to and inhibits the function of IL-15 in all of its forms (Cis, Trans, and soluble IL-15 bound to IL-15RA), and blocks IL-15-induced T cell proliferation. The molecule is currently in Phase II clinical evaluation for the treatment of vitiligo.

Vitiligo Pipeline Segmentation

Phases
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

For further information, refer to the detailed Vitiligo Pipeline report, visit here for Vitiligo Treatment Landscape @ https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Vitiligo Pipeline Report

• Coverage- Global

• Vitiligo Companies- Incyte Corporation, Amgen, Boston Pharmaceuticals, Arcutis Biotherapeutics, Pfizer, Dermavant Sciences, Clinuvel Pharmaceuticals, Celgene, TWi Biotechnology, AXIM Biotechnologies, Arrien Pharmaceuticals, and others

• Vitiligo Pipeline Therapies- Cerdulatinib, Ruxolitinib, AC-1101, ATI-1777, QLT-450, AMG 714, PF-06651600, ANB030, ARQ-252, BNZ-1, TT-01, and others.

• Vitiligo Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Vitiligo Market Drivers and Vitiligo Market Barriers, click here @ Vitiligo Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Introduction
2. Executive Summary
3. Vitiligo: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Vitiligo - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Vitiligo Collaboration Deals
9. Late Stage Products (Phase III)
10. Ruxolitinib: Incyte Corporation
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. AMG-714: Amgen
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. BOS 475: Boston Pharmaceuticals
17. Drug profiles in the detailed report…..
18. Early Stage Products (Preclinical)
19. ARQ-252: Arcutis Biotherapeutics
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Vitiligo Key Companies
23. Vitiligo Key Products
24. Vitiligo- Unmet Needs
25. Vitiligo- Market Drivers and Barriers
26. Vitiligo- Future Perspectives and Conclusion
27. Vitiligo Analyst Views
28. Vitiligo Key Companies
29. Appendix

Got Queries? Find out the related information on Vitiligo Mergers and acquisitions, Vitiligo Licensing Activities @ Vitiligo Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

This release was published on openPR.